NASDAQ: VBIO · Life Sciences · 14 alerts · CIK 1787740
Share price
$0.5290Close, Nov 16
Market cap
$11.7M
Shares outstanding
22.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗
Valion Bio held a special meeting of stockholders on November 12, 2026, where shareholders approved three key proposals. These included granting the board discretionary authority to effect a reverse stock split (ratio between 1-for-2 and 1-for-12) and amending the 2021 Equity Incentive Plan to increase the authorized share reserve by 272,000 shares.
Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.
Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.
Valion Bio, Inc. entered into side letters to issue Series B and Series C Preferred Shares and warrants for total proceeds of approximately $4.77 million. The transaction includes a $50,000 Series B closing with 3i, LP and a $4.72 million Series C closing with existing purchasers, part of which satisfies overdue cash true-up obligations.
Valion Bio has received unsolicited acquisition inquiries from third parties regarding its wholly owned CDMO subsidiary, Velocity Bioworks. The company has retained an investment bank to evaluate strategic options, including a potential sale, while prioritizing the retention of manufacturing rights for its lead drug candidate, Entolimod.
Interim CEO Dean Zikria released a 30-day strategic assessment focusing on advancing the Entolimod clinical pipeline and commercializing the company's Velocity Bioworks CDMO unit. The company is exploring strategic partnerships and licensing deals to bridge the gap between its scientific assets and current market valuation.